{
    "type": "ETP",
    "ucits": true,
    "replication_method": "synthetic",
    "swaps": true,
    "derivatives": true,
    "leverage": true,
    "inverse": true,
    "complex_factors": [
        "Leverage",
        "Inverse exposure",
        "Synthetic replication",
        "Use of futures contracts",
        "Daily reset and compounding effect",
        "Counterparty risk implied by collateralised debt security structure"
    ],
    "classification": "complex",
    "supporting_data": "The WisdomTree BTP 10Y 3x Daily Short is a UCITS eligible Exchange Traded Product (ETP) that provides leveraged inverse exposure (-3x) to the Long Term BTP Rolling Future Index via futures contracts. The product uses synthetic replication through futures contracts and is fully collateralised, indicating derivative usage and counterparty risk. The leverage factor of 3x and inverse exposure are explicit complexity triggers. The daily reset of leverage introduces a compounding effect, making returns non-linear and more difficult to understand. The product is classified as a collateralised debt security, which adds structural complexity and counterparty exposure. The risk indicator is at the highest level (7/7), reflecting the high risk and complexity. The KIID explicitly states the product is 'not simple and may be difficult to understand' and is intended for informed investors with specific knowledge. The product does not use physical replication but synthetic exposure via futures, confirming derivative use is inherent to the strategy rather than risk management. No capital protection or structured contingent features are mentioned, but the leverage, inverse exposure, and synthetic replication alone suffice for complexity classification under MiFID II. The costs include transaction costs related to underlying futures and management fees, but no performance fees. The recommended holding period is 1 day, highlighting the product's short-term trading nature and complexity due to daily leverage reset and compounding. Overall, the combination of synthetic replication, leverage, inverse exposure, and derivative use leads to a clear classification as a complex financial instrument under MiFID II."
}